Resultados de la búsqueda 181-190 of 14854 for Pap Smear Progress
Patients in the GDC-0199+R arm will continue GDC-0199 treatment until disease progression or 2 years since treatment start, whichever comes first.
Jacksonville, Fla. The purpose of this study is to determine if LIF (Leukemia Inhibitory Factor) level is positively correlated with disease progression and ...
ADPKD is a leading cause of end-stage renal disease. Recently, a new medication called Tolvaptan has been approved by the FDA to slow progression of ADPKD.
The primary study hypothesis is that pembrolizumab will prolong progression ... A Study to Evaluate the Impact of Non-invasive Tests for Bladder Cancer.
Patients will receive treatment until disease progression, unacceptable toxicity, consent withdrawal or death occurs. The study is expected to last ...
... progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD). ... Recently, a new medication called Tolvaptan has been approved by the FDA to slow ...
In this study, we make and test preclinical ... progression free survival, as compared to doxorubicin alone (Arm 1). ... Using these preclinical models, we will ...
The primary study hypothesis is that pembrolizumab will prolong progression-free survival (PFS) or overall survival (OS) compared to current SOC chemotherapy.
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?